Joseph Foss Email & Phone Number

Gates Mills, Ohio, Us

NeuroTherapia, Inc. is a start-up discovery and development company focussed on bringing new therapies that address neuroinflammation into the clinic. Our first compound is advancing and will enter human trials in 2018.

I am an investor and a member of the Prescreening Committee.

Cleveland, Ohio, Us

I work in the Department of General Anesthesiology in the Anesthesiology Institute. I am currently leading a project to bring NTRX-07 (previously known as MDA7), a promising new compound, from the bench to the bedside for the treatment of Alzheimer’s disease and neuropathic pain. I am a practicing anesthesiologist providing patient care. In collaboration with Cleveland Clinic Innovations I am working to identify promising discoveries from research at the Clinic which can be translated to clinical care. We have a joint development agreement with Parker Hannifin and I sit on the oversight committee which reviews and approves projects. As Director of Clinical Research in the department I also mentor staff who are interested in developing research projects in clinical anesthesiology. I am a Vice-Chair for the Institutional Review Board (IRB) and have an interest in the conduct of clinical trials and human subjects protection.

Non-profit organization using photography to promote environmental conservation.

Senior Director: Responsible for the design and direction of Phase 1-2-3 research studies on novel analgesics. The lead program for the company was the clinical development of alvimopan, a peripherally acting opioid antagonist. I was responsible for the studies to support the clinical pharmacology section of the label, as well as assisting with the Phase 3 program. I worked with our strategic partner, GSK, as the program liaison. I was also responsible for the translational program that was developing novel analgesics. I designed and managed two first-in-man trials for these new molecular entities as well as the proof of concept trials for the treatment of pain. I contributed to the NDA filing for alvimopan, which is now approved for clinical use (Entereg®), and filed two INDs, as well as participating in several FDA meetings.

Chicago, Il, Us

Anesthesiologist; Researcher: I led the development program for methylnaltrexone, a peripherally active opioid antagonist. This involved the proof of principle trials in pre-clinical models, the first-in-man studies, and subsequent proof of concept trials and studies of the pharmacokinetics and pharmacodynamics in man. I was responsible for the regulatory submissions during this period and had several meetings with the FDA. This work was funded in part by grants from the Rice Foundation, the Foundation for Anesthesia Education and Research, and Jannsen Pharmaceutica. Methylnaltrexone was licensed out and approved for clinical use (as Relistor®) in the management of opioid side effects in patients with advanced medical illness, such as cancer patients receiving opioids for palliative care. Director Preoperative Medicine Clinic. Member of advisory committee for GCRC.

Chicago, Il, Us

After completing my residency in Anesthesiology and Critical Care I did a one year fellowship in Clinical pharmacology with Leon Goldberg. I then worked on staff as an Assistant Professor doing both clinical work and research, primarily on methylnaltrexone.

M.D., Medicine

Bachelor Of Science (Bsc), Biology